An article from

Sy Mukherjee

Associate Editor

Sayak "Sy" Mukherjee is a former Associate Editor at Industry Dive, managing and writing content for BioPharma Dive and occasionally contributing to sister publication Healthcare Dive. Raised in sunny Orange County, CA, Sy is an avid fan of the Los Angeles Lakers, Green Bay Packers, movies, TV, music, and cooking. He received an A.B. from Dartmouth College in June 2012, double majoring in government (with a focus on public policy) and religious studies. Sy worked as a health reporter for ThinkProgress.org for a year and a half after graduating before joining Industry Dive in July 2014.

366 articles by Sy Mukherjee

Filter by Month:

Sanofi cashes in $245M review voucher to leapfrog Novo in crucial diabetes combo race
Feb. 24, 2016
Jury orders J&J to pay patient's family $72M in talcum powder-ovarian cancer case
Feb. 24, 2016
Double whammy: Valeant stock hammered on Philidor accounting issues, CVS Jublia restrictions
Feb. 23, 2016
Bayer to name new CEO to replace chief exec who transformed firm: report
Feb. 22, 2016
Biotech pioneer Alfred Mann resigns as Executive Chairman of struggling MannKind
Feb. 19, 2016
Cipla snatches 1st US manufacturing plant as part of 'landmark acquisition'
Feb. 18, 2016
Chasing blockbusters: Does pharma need to change its success strategy?
Feb. 18, 2016
One Louisiana doc's made millions blowing the whistle on big pharma. Is that problematic?
Feb. 18, 2016
UPDATE: AstraZeneca & Daiichi rebuff Vermont governor's call to pull OIC Super Bowl ad
Feb. 17, 2016
Aegerion chopping 25% of its workforce in global reorg, eyes pipeline growth
Feb. 12, 2016
India's Ipca slammed by FDA for litany of severe data violations
Feb. 11, 2016
Report: Walgreens threatened to dissolve Theranos arrangement barring quick fixes
Feb. 11, 2016
After strong FDA panel backing, Celltrion & Pfizer's Remicade copycat could become 2nd US biosim
Feb. 10, 2016
Obama budget's $825 million NIH boost could hit big snags over funding structure
Feb. 10, 2016
In blow to Sanofi, UK's NICE reverses course & backs Amgen's PCSK9 med
Feb. 9, 2016
Update: After patient deaths, FDA puts CTI BioPharma's myelofibrosis on full clinical hold
Feb. 8, 2016
UPDATE: Feds give Theranos one more week to respond to damaging CMS inspection
Feb. 5, 2016
How top Valeant & Turing execs defended their drug prices to Congress on Thursday
Feb. 5, 2016
Liability: The big biosim legal scuffle the industry should be anticipating
Feb. 4, 2016
Martin Shkreli goes to Washington—and refuses to say anything to Congress
Feb. 4, 2016
Senators urge Obama to ramp up pressure against high drug prices
Feb. 3, 2016
With steady Q4 earnings in hand, Glaxo chief requests 3 years for more consumer unit profits
Feb. 3, 2016
2016 sees its first US IPOs as biotechs Editas, BeiGene enter a turbulent market
Feb. 3, 2016
Pfizer's Q4 mixed bag spotlights its pipeline dilemma
Feb. 2, 2016
UK scientists win regulatory clearance to edit human embryo genes in CRISPR-Cas9 milestone
Feb. 1, 2016
Gilead chief Martin to step down from CEO role after 20 years
Jan. 29, 2016
Specialty injectables maker Sagent considering buyout with Cipla, Dr. Reddy's, others
Jan. 28, 2016
Massachusetts AG threatens Gilead with legal complaint over hep C drug prices
Jan. 27, 2016
Q4 earnings updates: Biogen beats on strong MS sales, no 'quick fix' on Alcon for Novartis
Jan. 27, 2016
Trump joins Clinton, Sanders, & Obama in endorsing Medicare drug price negotiations
Jan. 27, 2016
Sanofi EVP & former Obama admin official Suresh Kumar on the TPP, drug prices, & Dengue
Jan. 26, 2016
UPDATED: Feds to reportedly unveil new findings of 'serious deficiencies' at Theranos lab
Jan. 25, 2016
Walgreens CEO hops on the pricing critic train, says consumer Rx should be cheaper
Jan. 22, 2016
Cost control in the time of biopharma consolidation & globalization
Jan. 21, 2016
Pfizer reportedly mulling production expansion in Russia with Polysan
Jan. 21, 2016
Bombshell indictment accuses Glaxo scientists of stealing firm's trade secrets to sell in China
Jan. 21, 2016
After patient deaths, new Zafgen obesity med data revives approval hopes
Jan. 21, 2016
Shkreli & Valeant's interim CEO to face down Congress in pricing testimony next week
Jan. 20, 2016
NY strikes price cut, CVS distribution deal for Amphastar's heroin overdose antidote
Jan. 20, 2016
J&J to cut 3,000 jobs in major shakeup—is it a prelude to an acquisition?
Jan. 19, 2016
FDA harshly criticizes Sarepta's Duchenne drug just one day after rejecting BioMarin's
Jan. 15, 2016
Pfizer CEO: Our CAR-T development method could give us a leg up over Kite, Juno, Novartis
Jan. 14, 2016
JPM16 winds down: Valeant's pricing promise, J&J's small deal focus, & a murky biopharma outlook
Jan. 14, 2016
More from JPM16: Glaxo talks potential spinoff, 'Pfallergan' addresses future breakup scenario
Jan. 13, 2016
JPM16: An unprecedented cancer cure 'MoonShot,' Anthem threatens Express Scripts breakup
Jan. 13, 2016
JPM16 & BTS16: A dour start to biopharma's big week as stocks feel the pain
Jan. 12, 2016
Former Glaxo manager launches whistleblower suit over Nicoderm data
Jan. 8, 2016
J&J may sell off its Noramco manufacturing unit in $800 million deal
Jan. 7, 2016
3 key biopharma manufacturing stories to keep an eye on in 2016
Jan. 7, 2016
Could an old Roche arthritis med become a pioneering PAH treatment?
Jan. 7, 2016
Lilly's 2016 outlook dogged by exchange rates, buoyed by pipeline
Jan. 6, 2016
Valeant names former CFO Schiller interim CEO as Pearson remains hospitalized
Jan. 6, 2016
Sanofi & struggling MannKind ditch collab agreement amid Afrezza inhaled insulin flop
Jan. 5, 2016
Clinton unveils plan to find Alzheimer's cure by 2025 with $20 billion in NIH funding
Dec. 22, 2015
UPDATE: Shkreli resigns post as Turing Pharma CEO, kicked out of KaloBios
Dec. 21, 2015
Defiant Shkreli hits back at feds, says arrest was driven by his price hikes
Dec. 21, 2015
UPDATED: House passes $1.1T spending bill with NIH boost, pediatric review voucher extension
Dec. 18, 2015
Why Martin Shkreli's arrest won't take the heat off the biopharma industry
Dec. 18, 2015
How biopharma and media are reacting to Shkreli's arrest
Dec. 17, 2015
Martin Shkreli arrested by FBI on securities fraud charges related to former firm
Dec. 17, 2015
Valeant notches big win with 20-year Walgreens distribution deal, but slashes earnings forecasts
Dec. 16, 2015
Shkreli's latest acquire-and-hike antics spotlight review voucher critics' biggest fears
Dec. 15, 2015
The new PCSK9 scorecard: Praluent favored by UnitedHealth, Repatha by CVS, both by Express Scripts
Dec. 11, 2015
Sprout CEO Cindy Whitehead heads for the exits amid lackluster Addyi launch
Dec. 11, 2015
UPDATE: FDA places complete hold on Zafgen obesity med trials after 2nd patient death
Dec. 3, 2015
REPORT: Key lawmakers own major stakes in biopharma, healthcare firms they oversee
Dec. 1, 2015
How pharma is trying to get patients to stay on their meds—and out of the hospital
Nov. 30, 2015
Will a defiant Northwest Bio shy away from a financial investigation by an FBI vet?
Nov. 30, 2015
So your biopharma got fined millions by the feds—Where does that money go?
Nov. 25, 2015
The 'Pfallergan' fallout: Reactions to—and questions for—the biggest healthcare deal of all time
Nov. 24, 2015
UPDATED: Pfizer, Allergan agree to historic $160 billion inversion merger
Nov. 23, 2015
Pfizer, Allergan reportedly prepping record $150B merger ahead of new inversion rules
Nov. 19, 2015
Senators grilled Obama's nominee for FDA chief. Here's how he responded
Nov. 18, 2015
Liver Meeting '15 wrapup: Battling more hep C genotypes, shortening treatment regimens
Nov. 18, 2015
Liver Meeting '15: AASLD calls out payers on HCV med coverage; WHO's plan to wipe out hep C & B by 2030
Nov. 17, 2015
Liver Meeting 2015: Merck combo shines for IV drug abusers, Genfit preps phase 3 for pioneering NASH med
Nov. 16, 2015
3 charts that show how VC funding in life sciences reached all-time highs in Q3
Nov. 13, 2015
Perrigo shareholders handily reject Mylan's $26B hostile takeover bid
Nov. 13, 2015
Burdened with languishing Afrezza sales, MannKind sells off shares to Israeli bourse
Nov. 11, 2015
Judge: Valeant and Bill Ackman can't dodge Allergan investors' insider trading suit
Nov. 11, 2015
Outer space: The final frontier of biopharma R&D
Nov. 11, 2015
No 'purple pill' for Dr. Reddy's—court sides with AZ, blocks Nexium generic over coloration
Nov. 10, 2015
Under siege, Valeant chief insists short-term hits will give way to long-term gains
Nov. 10, 2015
Report: Amgen wants to get off the M&A sidelines, pursue $10 billion deal
Nov. 9, 2015
Feds: Medicaid programs restricting pricey hep C med access may be violating law
Nov. 6, 2015
Cellectis makes history as CAR-T therapy clears terminal leukemia in baby girl
Nov. 6, 2015
OxyContin gets political as Jeb Bush slams label expansion for kids, excess prescriptions
Nov. 5, 2015
House Dems launch drug pricing 'task force,' demand Turing & Valeant CEO subpoenas
Nov. 4, 2015
The next HIV breakthrough? Glaxo, J&J's long-acting shot as effective as 3-pill daily combo
Nov. 3, 2015
Valeant severs ties with controversial specialty pharma after mass PBM exodus
Oct. 30, 2015
UPDATE: Walgreens to snap up Rite Aid at 48% premium, forming drug store giant
Oct. 27, 2015
3 earnings beats and a miss: Examining Pfizer, Merck, Bristol-Myers, and Novartis' Q3
Oct. 27, 2015
How Valeant tried to defend itself on Monday morning's investor call
Oct. 26, 2015
Armed with earnings beat, defiant Shire to persist in Baxalta bid
Oct. 23, 2015
What in the world is going on at Valeant? A guide to what we know so far
Oct. 22, 2015
Valeant trading at 52-week low on report alleging 'phantom pharmacies' & fake sales
Oct. 21, 2015
23andMe relaunches expanded genetic tests after 2-year, FDA-mandated hiatus
Oct. 21, 2015
A bipartisan bashing: Rubio slams drug prices, pharma's 'pure profiteering'
Oct. 20, 2015
Massive gov't study promotes smaller drug doses, more talk therapy for schizophrenia
Oct. 20, 2015
Feds investigating Valeant's drug pricing, patient assistance programs
Oct. 15, 2015
The curious case of Zafgen's stock and a phase 3 patient death
Oct. 15, 2015
The 'best-performing' CEO in the world is a pharma chief
Oct. 14, 2015
Lilly faces crushing setback as it's forced to abandon lead heart drug
Oct. 12, 2015
Pharma CEOs head to WH to hear Obama's TPP pitch; Clinton comes out against trade deal
Oct. 8, 2015
Pharma giants join forces to squash CA drug price cap initiative
Oct. 8, 2015
Express Scripts to cover both Sanofi/Regeneron's & Amgen's PCSK9 meds
Oct. 7, 2015
TPP trade deal reached, BIO & PhRMA unhappy with drug patent compromise
Oct. 5, 2015
10 top trends driving the biopharma industry today
Oct. 1, 2015
Another kidney cancer hopeful: Exelixis med reduces tumor progression, death risk
Sept. 29, 2015
BIO kicks out Shkreli, Turing Pharma in wake of Daraprim price debacle
Sept. 24, 2015
Is Martin Shkreli biopharma's unwitting whistleblower?
Sept. 23, 2015
Perrigo gets personal, urges shareholders to reject Mylan hostile bid & keep shares
Sept. 17, 2015
UPDATE: Obama nominates Robert Califf as next FDA commissioner
Sept. 16, 2015
ICER: Novartis' expected heart failure mega-blockbuster overpriced just 17%
Sept. 15, 2015
Pill of the future? FDA to review first-ever 'digital medication' application
Sept. 11, 2015
Novartis to join forces with Google, launch human tests for 'smart' contacts
Sept. 8, 2015
US biosimilar era officially dawns as Novartis' Zarxio launches Thursday
Sept. 2, 2015
Google life sci strikes another big pharma research collab, this time with Sanofi
Aug. 31, 2015
Pricing & dosing controversies: What to expect after Amgen's new PCSK9 approval
Aug. 28, 2015
UPDATE: Biotech, pharma stocks rally after a roller coaster Monday
Aug. 25, 2015
Valeant strikes $1B deal to snag women's libido drug maker Sprout
Aug. 20, 2015
UPDATE: Sprout plots hiring binge after controversial female libido drug approval
Aug. 18, 2015
Juno loss widens in Q2 as R&D costs skyrocket
Aug. 14, 2015
Roche snaps up diagnostics firm for $425M as part of antibiotics refocus
Aug. 14, 2015
To reinflate lung portfolio, Glaxo needs Breo to shine where Advair failed
Aug. 14, 2015
Tracking Parkinson's patients for a drug trial? Roche has an app for that
Aug. 14, 2015
Avalanche shares continute to fall off a cliff as company ditches eye drug trial
Aug. 14, 2015
Will Dodd-Frank's CEO-worker pay ratio rule put the heat on pharma chiefs?
Aug. 13, 2015
Cancer Letter journo fights Amgen subpoena in shareholder suit
Aug. 13, 2015
Soaring drug costs at heart of military funding scuffle
Aug. 13, 2015
AbbVie, Genentech to seek US approval of potential blockbuster leukemia med
Aug. 12, 2015
Clovis & Genentech team up to test out a promising lung cancer combo
Aug. 12, 2015
FDA chastizes Duchesnay, Kim Kardashian over drug promo posts
Aug. 12, 2015
UPDATE: Glaxo to reopen NC plant this weekend after Legionnaires' scare
Aug. 12, 2015
Bill Gates gets in on the CRISPR/Cas9 frenzy with Editas backing
Aug. 11, 2015
UK's Mallinckrodt to buy US immunotherapy firm Therakos for $1.33B
Aug. 11, 2015
What will Google's huge 'Alphabet' restructure mean for its life sci ambitions?
Aug. 11, 2015
FDA loses off-label marketing suit against Amarin in major setback
Aug. 10, 2015
CVS to adopt 'wait and see' approach on PCSK9 cholesterol meds
Aug. 10, 2015
Shire offers $30B for Baxalta with sights on becoming rare disease titan
Aug. 4, 2015
Finally: Merck Ebola vax triumphs in phase III trial, overcoming logistical nightmare
July 31, 2015
Sanofi surprises in Q2 with strong MS sales, AZ slides on generic competition
July 30, 2015
Blockbuster Friday: Sanofi/Regeneron wins first US approval of PCSK9 cholesterol med
July 24, 2015
3 major earnings updates: Bristol-Myers, Lilly, & Valeant all soar past expectations
July 23, 2015
A mixed bag: Biogen's & Lilly's hotly anticipated Alzheimer's data are inconclusive
July 22, 2015
House overwhelmingly votes to pass 21st Century Cures FDA reform bill
July 10, 2015
Novartis set to redraw the heart failure map with rapid approval of game-changer Entresto
July 8, 2015
Teva plans to hike Mylan bid by $2B to $43 billion this week: report
July 7, 2015
AstraZeneca, Teva to shell out $54M to settle Medicaid rebate underpayment claims
July 7, 2015
Iowa State scientist sentenced to 57 months in prison for HIV vax trial fraud
July 2, 2015
Supreme Court OKs use of controversial drug for US executions
June 29, 2015
With new Cosentyx data, Novartis slated to nab huge psoriasis market share
June 29, 2015
How Titan Pharma wants to make implants the drug delivery systems of the future
June 25, 2015
EXCLUSIVE: An interview with Sanofi's president of North American pharma
June 24, 2015
A MedImmune SVP dishes on nanomed, antibiotic resistance, & his advice for biopharma
June 23, 2015
Biopharma titans Kite, Bluebird join forces to tackle HPV cancers
June 22, 2015
BIO2015: The next 'plastics' of biotech and a barreling towards another record M&A year
June 19, 2015
Your BIO2015 guide: Biotech in space, a BIO name change and more
June 18, 2015
BIO2015: Vertex founder tells VCs to cool it on the science, stick to investment
June 17, 2015
Pharma's Fortune 500: The top ranked companies of 2015
June 12, 2015
Biogen, Shire, Allergan top list of 'greenest' corporations in the world
June 11, 2015
Amgen PCSK9 drug gets FDA staff rec, but panelists express concerns
June 10, 2015
Biosim war heats up as Merck's Remicade & Enbrel biosimilars bag major wins in RA
June 10, 2015
Another day, another barb: Teva calls Mylan's anti-takeover tactics 'desperate'
June 9, 2015
Titan Pharma's opioid addiction implant shows promise in phase III
June 8, 2015
How VC funding for biotech has fundamentally changed—and what it means for the industry
June 3, 2015
A final ASCO15 roundup: Docs slam prices for meds, ImmunoGen eyes redemption, Puma gets hammered
June 2, 2015
ASCO15: BMS' new standard for melanoma, Celldex's brain cancer vax, Clovis' ovarian cancer win
May 31, 2015
Your ASCO15 guide: A mixed bag for Bristol-Myers, big wins for Merck, J&J
May 30, 2015
3 major trends driving layoffs in biotech and pharma
May 27, 2015
Bluebird shares more data on its breakthrough gene therapy trials, and it continues to impress
May 22, 2015
House committee unanimously passes 21st Century Cures FDA reform bill
May 21, 2015
CVS to buy nursing home pharmacy Omnicare for $12.7 billion
May 21, 2015
Top FDA official: Listing detailed drug risks in pharma TV ads a 'waste of time'
May 20, 2015
Bluebird cuts deal with regulators, plots path to first-ever US gene therapy approval
May 19, 2015
Industry, advocate pressure helps revive key 21st Century Cures exclusivity incentives
May 14, 2015
UPDATE: Takeda threatens to break off Orexigen collab after Contrave data drama
May 13, 2015
Mylan chairman thinks Teva a bad cultural fit, would consider buying it anyway
May 11, 2015
Glaxo's new chairman signals support for embattled CEO Witty
May 8, 2015
Alexion to buy Synageva BioPharma in $8.4B rare disease megadeal
May 6, 2015
IBM's Watson Health to collab with 14 major oncology centers on cancer genomics
May 6, 2015
Pfizer animal med spinoff Zoetis could axe 25% of workforce after Ackman pressure
May 5, 2015
The 10 brand name drugs that cost Medicare Part D the most money in 2013
April 30, 2015
Inside one pharma's mission to make a transdermal patch for insulin, vaccines, and more
April 30, 2015
4 big changes you need to know about the latest draft of 21st Century Cures
April 30, 2015
3 key lessons industry leaders have learned from the latest Ebola crisis
April 28, 2015
How Virginia's governor plans to get his state into the life sciences game
April 24, 2015
Strong cancer drug sales drive Roche to an impressive Q1
April 22, 2015
Merck CEO Kenneth Frazier elected as PhRMA's next board chairman
April 16, 2015
Regeneron CEO to join NY Gov. Cuomo on historic Cuba trade trip
April 16, 2015
IBM joins forces with J&J, Medtronic, Apple in ambitious clinical research data pact
April 15, 2015
UPDATE: FDA says key AstraZeneca diabetes drug may 'significantly' increase death risk
April 13, 2015
Sanofi digs in heels, won't discount Lantus insulin successor Toujeo
April 13, 2015
Pharmacy giant Walgreens to shutter 200 US stores by 2017
April 10, 2015
3rd largest Medicaid program didn't spend a dime on Sovaldi due to high cost
April 9, 2015
UPDATE: Mylan offers $29 billion to buy Perrigo, create generics powerhouse
April 8, 2015
Bristol-Myers sends uniQure soaring with $1B cardiovascular gene therapy deal
April 6, 2015
4 big biopharma deals we might see in 2015
April 6, 2015
Could NYC become the next big biotech hub?
April 2, 2015
Pfizer to immediately cease vaccine sales in China over licensing spat
April 2, 2015
Takeda offers $2.2 billion in massive Actos class action settlement proposal
April 1, 2015
Sarepta CEO resigns abruptly amid tense relationship with FDA
April 1, 2015
The M&A train rolls on: Teva to buy American CNS drug maker for $3.2B
March 30, 2015
Obama administration releases first major long-term 'superbug' response plan
March 27, 2015
Lilly slams Indiana's new 'religious freedom' law
March 27, 2015
Gilead CEO John Martin's true compensation could be $600 million
March 25, 2015
Is Amgen's genomic map of Iceland the ghost of personalized med's future?
March 25, 2015
ICYMI: Why 2015 is the year of the biopharma blockbuster (with charts)
March 24, 2015
Biogen Idec rebrands as Biogen, bets big on neurodegenerative pipeline
March 23, 2015
Biogen soars as Alzheimer's drug data shows sharp slowdown in cognitive decline
March 20, 2015
FDA panel says Glaxo asthma drug isn't proven safe for teens
March 20, 2015
Amgen, Sanofi PCSK9 drugs shown to cut CVD risk in half
March 16, 2015
UPDATE: Valeant successfully fends off Endo, seals deal with Salix
March 16, 2015
A steady March of job cuts: Amgen to axe 40% of remaining Onyx staff
March 10, 2015
FDA New Drugs chief: Orexigen's sunny Contrave heart data 'likely false'
March 6, 2015
AbbVie beats out J&J, will buy Pharmacyclics for $21B to boost cancer pipeline
March 5, 2015
SEC to pharma: Don't get cute with disclosing FDA dealings to investors
March 4, 2015
FDA approves Actavis' QIDP-designated antibiotic combo
Feb. 26, 2015
UPDATE: Sanofi's likely blockbuster insulin Toujeo wins FDA approval
Feb. 25, 2015
Game time: Remicade biosims from Celltrion, Hospira launch in big EU markets
Feb. 25, 2015
Pfizer planning more layoffs in R&D
Feb. 24, 2015
Engineering cures for metabolic diseases: A conversation with a Stanford biochemist
Feb. 24, 2015
In historic reversal, FDA approves 23andMe genetic test for Bloom Syndrome
Feb. 20, 2015
UPDATE: Valeant to buy Salix for $10.1B, cleared for $495M Dendreon buyout
Feb. 20, 2015
UPDATE: Bayer HealthCare chief Brandicourt named Sanofi's next CEO
Feb. 19, 2015
3 charts that show why 2014 was a record year for US orphan drugs
Feb. 17, 2015
Eisai, Pfizer, and Novartis meds get FDA love over the long weekend
Feb. 13, 2015
Hospira CEO's golden parachute for Pfizer deal: $80 million
Feb. 12, 2015
UPDATED: Sanofi to chop 100 US jobs in oncology R&D, Genzyme reorg
Feb. 11, 2015
Citi analyst: Humira biosims will hurt AbbVie sales more than you think
Feb. 11, 2015
Gilead to open London HQ, double UK workforce
Feb. 10, 2015
A faster cure? Achillion med mixed with Sovaldi clears hep C in just 6 weeks
Feb. 9, 2015
Sanofi: Q4 earnings beat forecast, new CEO to be named by end of Q1 2015
Feb. 5, 2015
UPDATED: FDA chief Hamburg to resign at end of March
Feb. 5, 2015
Earnings roundup: Merck tops expectations, steady GSK rises on ViiV IPO talk
Feb. 4, 2015
UPDATE: Why Gilead's shares are tumbling despite stellar Q4 earnings
Feb. 3, 2015
UK first in world to legalize '3-person DNA' babies to curb genetic disorders
Feb. 3, 2015
Sanofi finally launches Afrezza inhaled insulin in the US
Feb. 3, 2015
UPDATE: Obama budget proposes historic, direct Medicare drug price negotiations
Feb. 2, 2015
Obama to unveil $215M personalized medicine, million-person DNA sequencing project
Jan. 30, 2015
Greed is misunderstood? Tackling biopharma's pricing image problem
Jan. 29, 2015
4 things you need to know about the sweeping FDA reform bill Congress just proposed
Jan. 28, 2015
Expiring patents, surging dollar dog BMS, Pfizer, & Novartis earnings
Jan. 27, 2015
Sanofi/Regeneron off to the races with priority review of cholesterol game-changer
Jan. 26, 2015
UPDATED: Sen. Elizabeth Warren proposes big new pharma fines to fund NIH research
Jan. 22, 2015
REPORT: Takeda COO Weber approached for vacant Sanofi CEO post
Jan. 22, 2015
FDA approves likely Novartis psoriasis blockbuster Cosentyx
Jan. 21, 2015
Obama proposes genetic 'Precision Medicine Initiative' at State of the Union
Jan. 21, 2015
BMS' new chief: COO Giovanni Caforio to replace CEO Andreotti in May
Jan. 20, 2015
4 key industry trends that will impact biopharma in 2015
Jan. 19, 2015
J&J gets $115 million cash to speed Ebola vax development
Jan. 16, 2015
Sarepta fights back, Sanofi/BI partner, and more from the last day of JPM15
Jan. 15, 2015
EXCLUSIVE: An interview with Sanofi EVP Pascale Witz at JPM15
Jan. 14, 2015
AbbVie's Humira/hep C plans, bluebird bio, NIH funding, and even more from JPM15
Jan. 14, 2015
Express Scripts, PCSK9s, Gilead, and Shire: More from JPM15 and BTS15
Jan. 13, 2015
BioMarin, Merck, and Sanofi: The biggest news so far from 'JPM15' and 'BTS15'
Jan. 13, 2015
Genentech and Google-backed 23andMe strike Parkinson's research deal
Jan. 7, 2015
Salix CEO Logan becomes second C-suite casualty of inventory spat
Jan. 6, 2015
CVS to favor Gilead hep C meds over AbbVie's, setting up showdown with Express Scripts
Jan. 5, 2015
Promising late-stage trial bodes well for Cempra's next-gen antibiotic
Jan. 5, 2015
Novo searching for successor to CEO Sørensen, who has big shoes to fill
Dec. 29, 2014
UPDATED: FDA grants BMS's novel Opdivo accelerated approval for advanced melanoma
Dec. 22, 2014
UPDATED: Express Scripts snubs Gilead, will only offer AbbVie's new hep C pill
Dec. 19, 2014
CVS Health: Harvoni being prescribed at 2.5 times the rate of Sovaldi
Dec. 19, 2014
The 14 drugs most likely to top global pharma sales in 2015 and 2020
Dec. 18, 2014
Historic: FDA approves first-ever system to cut blood transfusion infections
Dec. 17, 2014
The 11 biggest drug launches to watch in 2015
Dec. 15, 2014
ICYMI: 3 charts that show why 2014 was a milestone year for US novel drug approvals
Dec. 12, 2014
Merck, NewLink Ebola vax trial suspended over joint pain complaints
Dec. 11, 2014
Indian company first to the finish line with historic Humira biosimilar
Dec. 10, 2014
CEO of growing biopharma CRO killed in Maryland small jet crash
Dec. 9, 2014
UPDATED: Jury sides with AZ in crucial pay-for-delay case over Nexium generics
Dec. 5, 2014
CDC pushing Tamiflu, Relenza because current flu strain doesn't match vaccine
Dec. 4, 2014
Confirmed: GSK to chop 900 jobs, mostly in North Carolina, in massive reorg
Dec. 3, 2014
BioMarin makes $840M gamble, buys Prosensa and its orphan drugs
Nov. 24, 2014
The 14 best-performing CEOs in biotech and pharma
Nov. 21, 2014
US hep C, cancer, diabetes med costs drive global drug tab past $1 trillion mark
Nov. 20, 2014
HHS scraps regulations for 340B drug pricing program
Nov. 18, 2014
UPDATED: Actavis buys Allergan for $66 billion
Nov. 17, 2014
Cancer immunotherapy specialist Juno Therapeutics files for IPO
Nov. 17, 2014
Activist investor Bill Ackman's $2 billion fallback plan for Valeant
Nov. 12, 2014
Specter of antitrust charges looms as Justice Department probes generic price hikes
Nov. 11, 2014
Best of BD: Is the current antibiotic pipeline really that bad? [INFOGRAPHIC]
Nov. 11, 2014
Advocates slam protracted UK negotiations over Novartis meningitis B vaccine
Nov. 10, 2014
ICYMI: The top 18 pharma-backed candidates who won in last week's elections
Nov. 6, 2014
AstraZeneca lifts 2014 forecast, but how will it deal with Nexium patent expiration?
Nov. 6, 2014
Could the Sanofi CEO's firing doom a $150 million inhaled insulin deal?
Nov. 4, 2014
RAND study: Biosimilars could save US $44 billion in 10 years
Nov. 4, 2014
Uh-oh: 2/3 of UK docs defying new statin guidelines
Nov. 3, 2014
ICYMI: 5 movies where biopharma goes horribly wrong
Oct. 31, 2014
AZ scores FDA approval of once-daily diabetes fixed-dose combo pill
Oct. 30, 2014
Merck beats Q3 forecasts, scores another Keytruda 'breakthrough'
Oct. 27, 2014
BMS beats analyst expectations on strong cancer, RA drug sales
Oct. 24, 2014
Lilly's Q3 profits drop sharply, hammered by patent expirations
Oct. 23, 2014
The $5.3B Mylan-Abbott inversion deal won't go the way of AbbVie-Shire
Oct. 22, 2014
UPDATED: GSK, NewLink Ebola vaccine trials could launch this January in Africa
Oct. 21, 2014
Actelion chief says it's time for pharma to ditch tax-inversion mergers
Oct. 21, 2014
Sorry, Pfizer: FDA won't nix black box suicide warning for Chantix
Oct. 17, 2014
Game on: Amgen sues Sanofi, Regeneron over PCSK9 cholesterol drug patent
Oct. 17, 2014
AbbVie-Shire deal effectively dead in the water
Oct. 16, 2014
UPDATED: Mark Zuckerberg announces $25 million CDC donation to fight Ebola
Oct. 14, 2014
Report: 6 US Ranbaxy execs head for the exits before Sun Pharma merger
Oct. 13, 2014
Pfizer nabs FDA priority review for potential breast cancer blockbuster
Oct. 13, 2014
AZ faces Texas lawsuit over bribery, improper marketing of antipsychotic drug
Oct. 13, 2014
UPDATED: On to the next one: FDA approves new Gilead hep C combo pill Harvoni
Oct. 10, 2014
PhRMA sues feds, again, over controversial hospital orphan drug discount rule
Oct. 10, 2014
UPDATED: Chimerix plummets on news of Dallas Ebola patient's death
Oct. 8, 2014
Is the UK's NHS about to snub Sovaldi?
Oct. 8, 2014
BMS unexpectedly pulls application for hep C drug
Oct. 7, 2014
The revolution will be personalized: An interview with two Stanford geneticists
Oct. 1, 2014
Zogenix files for addiction-fighting version of controversial pain pill Zohydro
Oct. 1, 2014
Tekmira stock opens big on news of first US Ebola case
Oct. 1, 2014
FDA rejects anti-addiction rule that would ban crushable Ritalin, opiates
Sept. 30, 2014
Roche's Perjeta 'unprecedented' in extending breast cancer patients' lives
Sept. 29, 2014
Federal judge dismisses racketeering charges against AbbVie, Abbott
Sept. 26, 2014
US doc treated with Tekmira Ebola drug declared virus free
Sept. 25, 2014
FDA to review Otsuka and Lundbeck's potential schizophrenia game changer
Sept. 25, 2014
GSK names Royal Bank of Scotland head its next chairman
Sept. 25, 2014
Tax-inversion hopefuls balk at new White House plans to curb deals
Sept. 23, 2014
UPDATED: Tekmira tempers expectations as regulators clear Ebola drug for emergency use
Sept. 23, 2014
Auxilium: Endo's $2.2B takeover bid 'significantly undervalues' company
Sept. 22, 2014
UPDATED: GSK found guilty of bribery in China, fined record $489 million
Sept. 19, 2014
Lilly enters crowded diabetes field as FDA approves once-weekly Trulicity
Sept. 19, 2014
Instant pleasure: Vivus ED pill wins faster-acting 'on demand' label
Sept. 18, 2014
UPDATED: Report: Sovaldi dropout rate 4 times higher than in trials
Sept. 17, 2014
Gilead to allow Indian generics of pricey Sovaldi in developing nations
Sept. 15, 2014
Justice Department to seek contempt charges against Bayer
Sept. 12, 2014
Google's Calico pens development deal for Parkinson's, ALS-fighting compound
Sept. 11, 2014
FDA approves controversial weight loss pill Contrave
Sept. 11, 2014
Sanofi wants kids to game their way to diabetes control
Sept. 10, 2014
FDA narrowly rejects Actavis' blood pressure combo
Sept. 10, 2014
GSK, Gilead's pulmonary hypertension combo smashes goals in phase III trial
Sept. 8, 2014
Study: GSK Ebola vaccine effective, requires booster shot
Sept. 8, 2014
Pharmacist tied to tainted steroids, meningitis outbreak case arrested at airport
Sept. 4, 2014
Report: AZ-White House phone calls set off DC's tax-inversion backlash
Sept. 4, 2014
Google's Calico, AbbVie strike $1.5 billion R&D pact to fight age-related diseases
Sept. 3, 2014
Feds ink $25 million contract with Ebola drug maker Mapp Biopharma
Sept. 3, 2014
Bayer to finally bring world famous 'hangover cure' Berocca to US
Sept. 2, 2014
ZMapp saves Ebola-infected monkeys in 'monumental achievement'
Aug. 29, 2014
FDA OKs spinal cord injury stem cell trial for Asterias
Aug. 28, 2014
GSK's Ebola vaccine gets FDA go-ahead for phase I human trials
Aug. 27, 2014
Roche to buy CA-based biotech InterMune in $8.3 billion deal
Aug. 25, 2014
Medtronic execs, shareholders lock horns over tax-inversion deal
Aug. 22, 2014
The 4 pharma companies with the highest profit margins [Infographic]
Aug. 22, 2014
Hospira wins temporary restraining order against Precedex generics
Aug. 20, 2014
1000s of companies revolt against Obamacare medical device tax
Aug. 20, 2014
'Ice Bucket Challenge' defies skeptics, raises $22.9M for ALS research
Aug. 19, 2014
Hackers behind CHS data breach may have been targeting intellectual property
Aug. 18, 2014
FDA green lights Biogen MS drug
Aug. 18, 2014
Allergan names 30-year company vet next CFO amid Valeant chaos
Aug. 18, 2014
Black box warnings and drug market withdrawals, by the numbers
Aug. 15, 2014
UPDATED: FDA issues consumer warning on fake Ebola drugs
Aug. 15, 2014
Feds to investigate Valeant, Bill Ackman's Allergan takeover bid
Aug. 14, 2014
Merck sleeping pill Belsomra gets FDA approval
Aug. 13, 2014
UPDATED: WHO endorses experimental treatments for Ebola patients
Aug. 12, 2014
All gone for now: Ebola drug ZMapp supply exhausted
Aug. 12, 2014
GSK slapped with another bribery allegation
Aug. 12, 2014
Sanofi nabs rights to MannKind's inhaled insulin with $150 million deal
Aug. 11, 2014
WHO panel to debate ZMapp, ethics of experimental Ebola treatments
Aug. 11, 2014
GSK eases expectations on Ebola vaccine: 'Long, complex process'
Aug. 11, 2014
Chinese authorities imprison GSK sex tape investigator, wife
Aug. 8, 2014
Walgreens to buck tax-inversion trend, remain in Chicago after merger
Aug. 6, 2014
Allergan files federal lawsuit against Valeant, Pershing Square
Aug. 1, 2014
FDA unveils first-ever plans to regulate genetic diagnostic testing
Aug. 1, 2014
WHO plans $100 million emergency response as Ebola deaths top 700
July 31, 2014
President Obama slams tax-inversion mergers: 'An unpatriotic tax loophole'
July 24, 2014

Home
- Drug Discovery
- Clinical Trials
- M&A
- Regulatory
- Manufacturing
- Marketing
- Legal
- Corp News
Deep Dive
Opinion
Library
Events
Jobs

Get BioPharma Dive in your inbox

The free newsletter covering the top industry headlines

Select Newsletter: BioPharma Dive
Topics covered: clinical trials, drug development, regulatory affairs, and much more.
Daily view sample
Select Newsletter: BioPharma Dive: Manufacturing Weekly view sample
Select Newsletter: BioPharma Dive: Marketing Weekly view sample

By signing up you agree to our privacy policy. You can opt out anytime.